Why IDXX Is Soaring Today

Pet healthcare firm Idexx (IDXX) is jumping 10% after delivering better-than-expected fourth-quarter financial results. The midpoint of the company’s 2025 earnings per share guidance range also came in above analysts’ average outlook.

Idexx’s Q4 Results and Its 2025 Guidance

The company’s Q4 sales rose 5.8% versus the same period a year earlier to $954 million. That was $17.3 million above analysts’ average estimate. Its earnings per share climbed 13% year-over-year to $2.62. Analysts’ mean outlook was only $2.40.

A pharmacy counter stocked with diverse pet medications.

Turning to 2025 guidance, Idexx expects its EPS to come in at $11.74 – $12.24 or $11.99 at the midpoint of the range. Analysts’ mean estimate was $11.84.

However, the company provided 2025 sales guidance of $4.05 billion – $4.17 billion. The midpoint of the latter range is slightly below the average estimate of $4.15 billion.

Idexx’s Comments

“In Q4, we began shipping the IDEXX inVue Dx™ Cellular Analyzer, our transformational slide-free cellular analyzer, and we plan to make IDEXX Cancer Dx™ screening for canine lymphoma available in late March 2025 in the U.S. and Canada. These types of innovations are highly sought-after by our customers,” CEO Jay Mazelsky said in a statement.

The Price Action of IDXX Stock

In the last month, the shares have climbed 8%, while they have risen 12% in the last three months.

While we acknowledge the potential of IDXX, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IDXX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.